@article{02d544e62cbc4164bcc007a2a4d296ec,
title = "High-grade glioneuronal tumor with an ARHGEF2–NTRK1 fusion gene",
abstract = "Here, we report a highly unusual case of high-grade glioneuronal tumor with a neurotrophic tropomyosin receptor kinase (NTRK) fusion gene. A 13-year-old girl presented with headache and vomiting and MRI detected two cystic lesions bilaterally in the frontal areas with surrounding edema. The left larger tumor was removed by left frontal craniotomy. The tumor was diagnosed as a high-grade glioneuronal tumor, unclassified. Methylation profiling classified it as a diffuse leptomeningeal glioneuronal tumor (DLGNT) with low confidence. This tumor showed genotypes frequently found in DLGNT such as 1p/19q codeletion without IDH mutation and, however, did not have the typical DLGNT clinical and histological features. RNA sequencing identified an ARHGEF2 (encoding Rho/Rac guanine nucleotide exchange factor 2)–NTRK1 fusion gene. The presence of recurrent NTRK fusion in glioneuronal tumors has an important implication in the clinical decision making and opens up a possibility of novel targeted therapy.",
keywords = "1p19qLOH, NTRK1, Pediatric brain tumor, RNA sequencing",
author = "Kazuhiko Kurozumi and Yoshiko Nakano and Joji Ishida and Takehiro Tanaka and Masatomo Doi and Junko Hirato and Akihiko Yoshida and Kana Washio and Akira Shimada and Takashi Kohno and Koichi Ichimura and Hiroyuki Yanai and Isao Date",
note = "Funding Information: We wish to thank Y Otani, T Shimizu, Y Tomita, Y Hattori, Y Matsumoto, and A Uneda, the Department of Neurological Surgery of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences for DNA sequencing and immunohistological staining, Y Shimada, Division of Genome Biology, National Cancer Center Research Institute for RNA sequencing, M Arao and U Ukai for their technical assistance. Central pathology review was performed by Japan Children?s Cancer Group (JCCG). This work was supported in part by the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED (J.H., T.K and K.I). In addition, we thank Dr. Trish Reynolds, MBBS, FRACP, from Edanz Group (www.edanzediting.com/ac) for editing the English text of a draft of this manuscript. Publisher Copyright: {\textcopyright} 2019, The Japan Society of Brain Tumor Pathology.",
year = "2019",
month = jul,
day = "25",
doi = "10.1007/s10014-019-00345-y",
language = "English",
volume = "36",
pages = "121--128",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",
number = "3",
}